ZA9610139B - Treatment of the cns effects of hiv - Google Patents

Treatment of the cns effects of hiv

Info

Publication number
ZA9610139B
ZA9610139B ZA9610139A ZA9610139A ZA9610139B ZA 9610139 B ZA9610139 B ZA 9610139B ZA 9610139 A ZA9610139 A ZA 9610139A ZA 9610139 A ZA9610139 A ZA 9610139A ZA 9610139 B ZA9610139 B ZA 9610139B
Authority
ZA
South Africa
Prior art keywords
hiv
treatment
cns effects
cns
effects
Prior art date
Application number
ZA9610139A
Other languages
English (en)
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA9610139B publication Critical patent/ZA9610139B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9610139A 1995-12-05 1996-12-03 Treatment of the cns effects of hiv ZA9610139B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV

Publications (1)

Publication Number Publication Date
ZA9610139B true ZA9610139B (en) 1997-06-17

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610139A ZA9610139B (en) 1995-12-05 1996-12-03 Treatment of the cns effects of hiv

Country Status (23)

Country Link
US (1) US5646180A (pl)
EP (1) EP0866696B1 (pl)
JP (1) JP2000501713A (pl)
KR (1) KR19990071750A (pl)
CN (1) CN1203530A (pl)
AP (1) AP864A (pl)
AT (1) ATE279922T1 (pl)
AU (1) AU722850B2 (pl)
BR (1) BR9611861A (pl)
CA (1) CA2238471A1 (pl)
CZ (1) CZ291994B6 (pl)
DE (1) DE69633680T2 (pl)
ES (1) ES2231828T3 (pl)
HU (1) HUP9903673A3 (pl)
NO (1) NO317837B1 (pl)
NZ (1) NZ324603A (pl)
OA (1) OA10691A (pl)
PL (1) PL187747B1 (pl)
PT (1) PT866696E (pl)
RU (1) RU2203658C2 (pl)
UA (1) UA61902C2 (pl)
WO (1) WO1997020554A1 (pl)
ZA (1) ZA9610139B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
CZ429398A3 (cs) * 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
AU8017298A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
CA2393466C (en) 1999-12-21 2010-01-19 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
ES2243556T3 (es) * 2000-10-16 2005-12-01 Conor Medsystems, Inc. Dispositivo medico expandible para proporcionar un agente beneficioso.
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
ATE556706T1 (de) * 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
CA2648891A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3110381B1 (en) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治疗hiv的toll样受体(tlr)调节剂
BR112019012060A2 (pt) 2016-12-14 2020-03-10 Attends Healthcare Products Inc. Laminados absorventes, núcleos absorventes e artigos descartáveis utilizando os laminados absorventes e métodos relacionados
ES3019585T3 (en) 2018-05-28 2025-05-20 Attends Healthcare Products Inc Dryness layer laminate for absorbent articles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
HUP9903673A3 (en) 2000-08-28
BR9611861A (pt) 1999-05-18
US5646180A (en) 1997-07-08
EP0866696B1 (en) 2004-10-20
KR19990071750A (ko) 1999-09-27
PL327061A1 (en) 1998-11-23
CN1203530A (zh) 1998-12-30
PL187747B1 (pl) 2004-09-30
RU2203658C2 (ru) 2003-05-10
CZ170898A3 (cs) 1998-09-16
HUP9903673A2 (hu) 2000-03-28
NO982556L (no) 1998-06-04
AU1148697A (en) 1997-06-27
ES2231828T3 (es) 2005-05-16
AP9801340A0 (en) 1998-09-30
CA2238471A1 (en) 1997-06-12
NO982556D0 (no) 1998-06-04
AP864A (en) 2000-08-11
DE69633680T2 (de) 2006-02-23
ATE279922T1 (de) 2004-11-15
WO1997020554A1 (en) 1997-06-12
AU722850B2 (en) 2000-08-10
JP2000501713A (ja) 2000-02-15
NO317837B1 (no) 2004-12-20
CZ291994B6 (cs) 2003-07-16
NZ324603A (en) 2000-08-25
PT866696E (pt) 2005-03-31
OA10691A (en) 2001-05-04
DE69633680D1 (de) 2004-11-25
UA61902C2 (en) 2003-12-15
EP0866696A1 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
ZA9610139B (en) Treatment of the cns effects of hiv
GB2298440B (en) Well treatment
GB9215633D0 (en) Novel treatment
GB9226860D0 (en) Novel treatment
GB9519033D0 (en) Treatment
GB9203039D0 (en) Treatment
GB9211148D0 (en) Novel treatment
GB9225860D0 (en) Novel treatment
GB9226957D0 (en) Novel treatment
PL317876A1 (en) Combined treatment of hiv infections
AP9300527A0 (en) Novel treatment
GB9424471D0 (en) Treatment of emesis
GB9225859D0 (en) Novel treatment
GB9203637D0 (en) Novel treatment
HU9502697D0 (en) Drogs for the treatment of retrovirus infections
ZA968923B (en) The treatment of sewage
GB9503143D0 (en) Treatment of depression
GB9524086D0 (en) Novel treatment
GB9515569D0 (en) Novel treatment
GB9513449D0 (en) Novel treatment
GB9510065D0 (en) Treatment
GB9212535D0 (en) Treatment of boimass
GB9200360D0 (en) Treatment
GB9215903D0 (en) Treatment
GB9200359D0 (en) Treatment